Introduction
Uterine leiomyoma and adenomyosis represent the most common benign tumors of the female reproductive system (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008) . These tumors are estrogen dependent, develop during the reproductive period, and are suppressed with menopause. Traditional treatments for myomas and adenomyosis have been various types of surgical techniques. Medical management of these tumors is an approach that has been used recently and is attractive for many gynecologists because of its relative ease and lack of complications (pelvic organ adhesion) compared with surgery. Indications for therapy are similar to those for surgical removal of these tumors and focus on preserving fertility and/or the patient's desire to maintain her uterus. Medications used include androgens, antiprogestogens (mifepristone), raloxifen, and gonadotropin-releasing hormone agonist (GnRHa) (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008; Schweppe, 1999) . At present, considering efficiency and safety issues, none of the above agents obtained adequate popularity except for GnRHa. However, GnRHa also have disadvantages including bone loss and menopausal symptoms. The effect of GnRHa is transient and reversal of estrogen deprivation occurs soon after discontinuation of the GnRHa and most myoma and adenomyosis returns to their initial size within several months after discontinuation.
Dienogest is a selective progestin that combines the pharmacologic properties of 19-norprogestins and progesterone derivatives, offering potent progestogenic effects without androgenic, mineral corticoid, or glucocorticoid activity (Harada & Taniguchi, 2010; Sasagawa et al, 2008; Sitruk-Ware, 2006) . Previous trials demonstrated that dienogest provides effective reductions in endometriosis-associated pelvic pain and laparoscopic measures of pathology (Harada et al, 2009; Köhler et al, 2010; Schindler et al, 2006; Strowitzki et al, 2010b) . Recently, the new progesterone 2 mg daily demonstrated equivalent efficacy to GnRHa (e.g. buserelin acetate and leuprolide acetate) for relieving the pain of endometriosis in two 24-week, randomized studies (Harada et al, 2009; Strowitzki et al, 2010a; Strowitzki et al, 2010b) . Because uterine myoma/adenomyosis and endometriosis have many common features (Huang et al, 2010) , these successful trials on endometriosis support that the use of dienogest inhibits myoma and adenomyosis growth. While evaluating superiority of dienogest in women with endometriosis, we have found significant shrinkage of myoma nodes coexisted with endometriosis over several months during an administration of dienogest (Ichigo et al, 2011) . In this paper, we attempted to prevent their regrowth after discontinuation of GnRHa using dienogest. This retrospective study may be the first study that examined the efficacy and safety of dienogest following GnRHa therapy in perimenopausal women until leading to a natural menopause.
Materials and methods

Reproductive chart review
The data were collected from 13 perimenopausal patients sequentially treated with leuprolide acetate (1.88mg monthly, Takeda Pharmaceutical, Japan) for 6 months and dienogest (2mg/day, Mochida Pharmaceutical, Japan) for 6 months against endometriosis in our patient clinic from January 2008 to May 2011. In this retrospective chart review, we included all perimenopausal patients complicated with a myoma node measuring > 4cm or with adenomyosis measuring >10 cm at the age 46-52 years. Measurements of nodes or total uterine volume using MRI were performed at baseline and during treatment at months 6 and 12. For tecknical reasons, leuprolide acetate was supplied in vials and dienogest in tablets.
Size of myoma or overall uterine was measured at three diameters (transverse, vertical and anterior-posterior) with MRI. Half of multiplied three diameters was accepted as size of myomas and uterus. These measurements were repeated 6 and 12 months after starting the therapy.
Statistics
Pared t-tests were used to analyze in each size change from baseline. Statitstical significance was defined as P < 0.05. 
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The patients were sequentially treated with leuprolide acetate (1.88mg monthly) for 6 months and dienogest (2mg daily) for 6months. Measurements of nodes using MRI were performed at baseline, during treatment at months 6 (after GnRHa therapy) and 12 (after dienogest therapy).
# MRI changes of case 5 are presented as a representative prolile in Fig.1 . Table 1 ).
The patient was sequentially treated with leuprolide acetate (1.88mg monthly) for 6 months and dienogest (2mg daily) for 6months. Sagittal T2-weighed MR imagings before (a), months 6 (after GnRHa therapy) (b) and 12 (after dienogest therapy)(c)
Results
Of 13 endometriosis patients sequentially treated with GnRHa and dienogest, 7 were associated with coexistent myoma node and adenomyosis; 4 intramural and 2 subserosal types and 1 of adenomyosis. Mean age was 49.9 ± 2.3 (46-52)( Table 1) . Volume changes of total myoma and adenomyosis are presented as the percentage change from baseline in Table 1 . A remarkable reduction in myoma /adenomyosis volume from baseline was noted:
the total volume of myoma/adenomyosis declined to 67.6 ± 19.5 % after GnRHa treatment table 1). During the dienogest-period, myoma volume remained as they shrunk; no regrowth occurred. Fig. 1 showed as a representative profile (case 6 of Table 1 ). One patient (case 7) discontinued therapy because of an unexpected event, onset on ovarian abscess developed in the endometrioma (see Fig.2 ). The patient was treated with leuprolide acetate (1.88mg monthly, Takeda Pharmaceutical, Japan) for 6 months. Axial T2-weighed MR imagings before (a) and after (b) GnRHa treatment showed remarkable shrinkage of uterine myoma and bilateral endometriomas. An attempt to prevent the recurrence submitted the patient to dienogest therapy (2mg daily, Mochida Pharmaceutical, Japan). After two months, she complaint a one-week history of increasing abdominal girth and a two-day history of fever. Axial T2-weighed MR imaging (c) showed two enlarged cystic lesions, one in the left adnexa and the other in the right adnexa. Both lesions were superimposed on the endometrioma with inhomogenous content and the thick wall, while shrunk uterine myoma was detected. There was no history of gynecological interventions including endometrioma aspiration, no had she ever used an intra-uterine device. The clinical and imaging findings and unresponsive to antibiotic therapy proposed the ovarian abscess developed in the endometriomas. At laparotomy, both ovarian cysts were markedly distended and filled with yellow-brown pus, and both ovaries were destroyed by multiple abscess pockets. Histology of the abscess wall confirmed endometriotic nature of the cyst.
Discussion
Uterine myoma/adenomyosis and endometriosis have many common features. Both are estrogen-dependent conditions that can often be the source of pelvic pain and menstrual abnormalities. In addition, both have range of symptom severity that is often poorly correlated to preoperative or operative findings, making surgical planning a challenge (Huang et al, 2010 ). Recently we found significant shrinkage of myoma nodes coexisted with endometriosis over several months during an administration of dienogest (Ichigo et al, 2011) . To our knowledge this retrospective study may be the first study that examined the efficacy and safety of sequential management with dienogest following GnRHa therapy in perimenopausal women until leading to a natural menopause.
Many studies have reported the potential usefulness of the hypoestrogenic state induced by GnRHa for treatment of uterine myoma (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008) . A GnRHa down-regulates the pituitary-ovarian-gonadal axis, leading to suppression of ovarian steroidogenesis. In the present study our patients revealed an average reduction of 57.5 % in myoma volume in response to leuprolide acetae (1.8mg/month). The results are in agreement with those of previous studies (Levy, 2008; Parker, 2007; Parsanezhad et al, 2010; Sankaran & Manyonda, 2008) . The GnRHa treatment is often associated with so-called ovarian defect symptoms, including vasomotor instability, vaginal dryness, and significant bone loss, which preclude the long-term use of this compound (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008) . These limit the standard use of GnRHa to 6 months. The regression of uterine or endometriosis volume is not permanent, with returning to their original size or even enlarging more rapidly upon cessation of GnRHa administration. GnRHa, therefore, can only be used in the short term, as temporizing measures in the perimenopausal woman, or pre-operatively to reduce myoma size, influence the type of surgery, restore hemoglobin levels and apparently reduce blood loss at operation (Sankaran & Manyonda, 2008 ).
There may be profound differences among the available progestins according to their structure, metabolites and pharmacodynamic actions (Harada & Taniguchi, 2010; Sasagawa et al, 2008; Sitruk-Ware, 2006) . It is therefore inappropriate to consider the various effects of the older and newer progestins as class effects. While it has long been established that estrogen promotes myoma growth, many biochemical and clinical studies suggested that older progestins, without an estrogen component, may be effective in the treatment of endometriosis, but not adenomyosis or myomas (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008) . The newer progestin dienogest demonstrates a modest suppression of estradiol, representing a potential advantage over other therapies, such as GnRHa, which require estrogen add-back if used longer than 6 months (Harada & Taniguchi, 2010; Strowitzki et al, 2010a) . Also in contrast to GnRHa, dienogest is not associated with an increased incidence of hot flashes (Strowitzki et al, 2010a; Strowitzki et al, 2010b) . More recently the efficacy and safety of long-term usage of dienogest have been demonstrated in previous controlled studies in a large number of patients with endometriosis (Endrikat et al, 2007; Momoeda et al, 2009; Schindler et al, 2010; Sitruk-Ware, 2006) . Our previous paper demonstrated that the use of dienogest have several advantages over GnRHa therapy to manage uterine myoma (Ichigo et al, 2011) . Management of uterine myoma using dienogest is useful in women for whom temporary reduction in myoma volume is aimed and no surgical intervention is planned for any reason. Women with uterine myoma who have pain, pressure effect, hypermenorrhea, or other types of abnormal uterine bleeding who wish to retain the option of childbirth; women who wish to save their uterus; women who are not fit for surgical intervention; and young women with infertility can take advantage of this type of treatment. However, the total decline in myoma volume and controlling symptoms are greater in GnRHa protocol (Ichigo et al, 2011) . The benefit of dienogest in controlling symptoms may persist after therapy of GnRHa in perimenopausal women.
In the previous study (Imai et al, 2003) , because rapid regrowth frequently occurs after the therapy is stopped. we attempted to determine whether GnRHa therapy could lead perimenopausal women carrying symptomatic myomas to the natural onset of the menopause. A retrospective analysis of 145 patients who received GnRHa for 24 weeks demonstrated that after cessation of therapy no menstruation occurred over 25 weeks in women aged over 45 years, with elevated levels of follicle-stimulating hormone (FSH) and luteinising hormone (LH). To extend this observation, we studied prospectively 21 women, aged 45 years and older who had regular menstruation with symptoms attributed to myomas and elevated days 3 - 5 FSH and days 3 - 5 LH levels (> 25 mIU/ml). After discontinuation of GnRHa (leuprorelin acetate, 1.88 mg) therapy for 6 months, menstruation occurred in only two of 21 individuals but the remaining 19 cases had no menstrual bleeding. It is suggested that the rise in early follicular phase serum gonadotrophins, in particular FSH (> 25 mIU/ml), may precede the natural menopause following (or during) GnRHa therapy in older women. Measuring days 3 to 5 serum FSH concentrations may make it easier to decide on the optimal duration of therapy for symptomatic uterine fibroids in perimenopausal women aged > 45 years. However, in other words, approximately 10 % of women failed to become natural menopause.
Regarding an unexpected event of case 7 of table 1, she has no known previous history of pelvic inflammatory disease, IUD, or any surgical intervention, so she was very unlikely to present with ovarian abscess. It shows that an isolated ovarian abscess can develop in an endometrioma without any recognized risk factor. There are different theories about developing an abscess in the endometrioma (Hameed et al, 2010; Kavoussi et al, 2006) . It may be due to an altered immune environment within endometrial glands and stroma. Recent studies have shown that progesterone-like substances enhance the sexual transmission of various pathogens, including bacteria (Huber & Gruber, 2001; Vassiliadou et al, 1999) . Collection of altered menstrual type of blood in a cystic space in the ovary and can be a suitable culture medium for pathogens. Cystic wall of endometrioma is theoretically weak as compared to normal ovarian epithelium, so it is susceptible to bacterial invasion.
Lastly, we reported successful management of a series of patients with uterine myoma associated with endometriosis by sequential therapy with GnRHa and a progestine dienogest, although based on the finding in patients associated with endometriosis. The follow-up period of our study was too short to consider the recurrence rate of myomas after discontinuation of treatment in all subjects. Although prospective controlled study should be addressed, the use of dienogest treatment following GnRHa discontinuation for perimenopausal women with symptomatic uterine myoma or adenomyosis should be considered before choosing a more invasive interventions.
Conclusion
High recurrence rate rapidly after finishing GnRHa leads us to examine the efficacy of sequential management with GnRHa and dienogest in perimenopausal women with endometrisosis-associated uterine myoma. Consideration of GnRHa advantages on myoma
